Sorry to disagree but, imo, the financing decision says almost very little about "Harvey's confidence in Ridaforolimus in the SUCCEED trial." Ariad can't stop developing 534 AND 113 waiting for the Rida results. Rida is in Mercks hands and, given the delay, the company was faced with the choice to partner 534 now or raise $'s. Time will tell but I think they made the right choice. I just feel kind of stupid for not seeing this earlier.
News 
Market Data 
Discover 
